Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Destina Genomica S.L. is a specialized biotechnology company headquartered in Granada, Spain, focused on advanced chemical innovation for molecular diagnostics and drug development. Its website highlights “PCR-Free miRNA & Multi-Omic Detection,” with its core technology being the patented, platform-agnostic Destina Chemistry, designed to improve the detection accuracy of RNA biomarkers and their mimetics in complex samples.
Based on the collected content, Destina is not a traditional SaaS or enterprise software provider. Instead, it is a biotechnology platform for research and clinical translation scenarios. Its products include the RUO LiverAce SinglePlex Kit, RUO LiverAce COMBO Kit, and Peptide Nucleic Acids (PNAs), along with technology licensing opportunities. Its main value proposition is to address challenges such as RNA instability and the complexity of isomiR detection, bridging genomics research with routine clinical practice.
The website states that the chemistry is platform-agnostic and intended to integrate seamlessly with existing detection platforms, which could be valuable for laboratories with established testing workflows. However, the available text does not disclose specific compatible platforms, instruments, software interfaces, APIs, or developer documentation. On compliance, the company has begun building an ISO 9001-based quality management system, with certification targeted for June 2026; in the medium term, it plans to pursue ISO 13485. No details were found regarding data security, privacy protection, or medical data compliance.
The public materials do not provide packages, pricing, purchasing procedures, free trials, or sample policies. The business model may include sales of RUO kits, PNAs products, and licensing partnerships for Destina Chemistry, but the specific terms cannot be confirmed from the available text.
Its strengths lie in a focused technical positioning, targeting high-value use cases in RNA biomarkers and molecular diagnostics, while emphasizing compatibility with existing detection platforms. The weaknesses are limited public commercial information, a quality system still under development, and a lack of SaaS-related capabilities such as software features, permission management, APIs, and team collaboration. It is better suited for molecular diagnostics R&D teams, RNA biomarker researchers, clinical translation laboratories, and drug development organizations evaluating relevant technologies.
Access from China is unclear. The available text does not state whether the website can be reached reliably from mainland China, whether Chinese payment methods are supported, or whether there are local distribution channels. For Chinese teams considering procurement, it is advisable to confirm import qualifications, RUO-use boundaries, cold-chain logistics, after-sales response, and compliance documentation. Alternatives should be compared separately based on the specific application, such as molecular diagnostic reagents, miRNA detection platforms, or multi-omics testing services.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on destinagenomics.com official site.
destinagenomics.com is an United Kingdom Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach destinagenomics.com directly.